Navigation Links
GVAX in Medical News

Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer

Cell Genesys, Inc. (Nasdaq: CEGE) today announced follow-up data from a Phase 2 clinical trial of GVAX immunotherapy for pancreatic cancer which was conducted by the Johns Hopkins Sidney Kimmel Cancer Center. The trial enrolled 60 patients with operable pancreatic cancer who received GVAX after su...

Experimental Cancer Vaccines Show Promise

...ented Tuesday at the American Association for Cancer Research annual meeting, in San Diego. A second study, out of the Netherlands, found that the gvax vaccine stimulated a significant immune response in men with prostate cancer. Five out of six participants receiving the highest dose of vaccine showe...

Immunotherapy: enlisting the immune system to fight cancer

...ic hormone-refractory prostate cancer treated with gvax immunotherapy for prostate cancer and ipilumumab: ...phase I trial, they observed that a combination of gvax immunotherapy with ipilimumab lowered prostate-spe...s. Higher doses of ipilimumab combined with the gvax vaccine is showing a lot of success in increasing ...

Cell Genesys to Present at the Cowen and Company and the Lehman Brothers Healthcare Investor Conferences

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...

Cell Genesys Reports Fourth Quarter and Year-End 2007 Results

... potential association between immune responses to gvax immunotherapy for prostate cancer and increase...irst of two ongoing Phase 3 clinical trials of gvax immunotherapy for prostate cancer, completed a ... Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials ...

Combo Treatment Best for Melanoma, Advanced Ovarian Cancer

...ce a protein called GVAX. When the cells are then re-infused into patients, gvax acts like a siren to the immune system, prompting a more energetic attack o...mune response spurred by the vaccine, researchers studied whether combining gvax vaccines with monoclonal antibody therapy could lengthen remissions and que...

Vaccine/antibody therapy effective, milder side effects in melanoma and ovarian cancer

... When the cells are then re-infused into patients, gvax acts like a siren to the immune system, prompting ... researchers have begun studying whether combining gvax vaccines with monoclonal antibody therapy could le... patients who had previously been immunized with a gvax vaccine. The new study, a joint effort of Dana-...
GVAX in Medical Technology

Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer

SOUTH SAN FRANCISCO, Calif., Feb. 15 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ) today reports the results of an analysis examining the potential association between immune responses to GVAX immunotherapy for prostate cancer and increased patient survival in a Phase 2 trial i...

Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer

Conference Call Scheduled for 10:00 a.m. ET Today SOUTH SAN FRANCISCO, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ) today announced that the Independent Data Monitoring Committee (IDMC) for VITAL-1, the first of two ongoing Phase 3 clinical trials of...

Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer

SOUTH SAN FRANCISCO, Calif., April 03, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced final, updated results from its second multi-center Phase 2 trial of GVAX immunotherapy for prostate cancer which evaluated escalating doses of the immunotherapy in 80 patients with metastatic ...

Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response

SOUTH SAN FRANCISCO, Calif., April 17, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today reported immune response data from two previously conducted Phase 2 clinical trials of GVAX immunotherapy for prostate cancer. Evaluation of antibody responses in patients with advanced prostate cancer f...

Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology

...state Cancer Session) -- Oral presentation beginning at 11:30 a.m. local time on Monday, June 2, 2008. -- "Expanded phase 1 combination trial of gvax immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC)" (Abstract #5146, Geni...

Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting

... hormone-refractory prostate cancer treated with gvax immunotherapy for prostate cancer and ipilimum...limumab in combination with the Cell Genesys, Inc. gvax immunotherapy for prostate cancer (an investig...nsion cohort (3 mg/kg ipilimumab). The dose of gvax immunotherapy for prostate cancer used in this...

Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer

...ed follow-up data from a Phase 2 clinical trial of gvax immunotherapy for pancreatic cancer which was cond...ients with operable pancreatic cancer who received gvax after surgical resection of their tumor and adjuva...ent surgery and adjuvant therapy without receiving gvax indicated that the median overall survival of the ...
GVAX in Biological News

Combination therapy with a monocloncal antibody and a vaccine leads to tumor rejection

...eration and allows both Tregs and Teff cells to proliferate in response to exposure to self-antigen. Interestingly, combination of CLTA4 blockade with gvax selectively primes the anti-tumor Teff cells for action. This led to greater infiltration of Teff cells into the tumor, and eventually to tumor reject...
GVAX in Biological Technology

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...n Bavituximab in Prostate Cancer II-54 Cell Genesys Reveals Data of gvax Immunotherapy for Treatment of Prostate Cancer II-54 Bioponic Phyto...to Take Over Rights of a New Marker Technology II-78 Cell Genesys's gvax Prostate Cancer-Treatment Attains FDA's Fast Track Tag II-78 Envisi...

Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research

...pril 12-16, 2008 in San Diego: -- "Dendritic and T cell functions in patients with metastatic hormone- refractory prostate cancer treated with gvax immunotherapy for prostate cancer and ipilimumab" (Abstract #2538, Clinical Immunotherapy Session) - Oral presentation scheduled for Monday, A...

Cell Genesys to Present at the BIO CEO and Investor Conference

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...

Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...

Cell Genesys to Webcast Third Quarter 2007 Conference Call

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...

Cell Genesys to Present at the BIO Investor Forum

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...

Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double by 2016

...c cancer drug market to more than double by 2016. The new Pharmacor report entitled Pancreatic Cancer finds that Pharmexa's GV1001 and Cell Genesys's gvax will drive the market from $560 million in 2006 to $1.2 billion in 2016 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan....

Cell Genesys to Present at the Bear Stearns 20th Annual Healthcare Conference

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...
Other Tags
(Date:7/31/2014)... Joseph M. Lee, M.D., M.S., R.P.V.I, ... a leading provider of quality cardiovascular and internal medicine ... Dr. Lee is a board certified cardiologist with a ... addition to his position at CDHV, Dr. Lee is ... Columbia University Medical Center. Dr. Lee is board certified ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Women in ... take charge of their financial future. The Independent ... has opened registration for 6 upcoming Los Angeles area ... for women, and with input from Kim Kiyosaki, a ... It’s Rising Time) who is passionate about women’s financial ...
(Date:7/31/2014)... steadily in the U.S in recent years. According to ... number of individuals reporting past year heroin use almost ... suggests the increase may be linked to prescription opioid ... use to heroin use, with POs providing the entryway ... This drug-use trajectory appears to have become increasingly common ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Clifton Dental ... the application of topical fluoride treatments to their adult ... and help with tooth sensitivity in patients that exhibit ... an infection that is commonly known as “tooth decay” ... tissues of the teeth. , Fluoride therapy ...
(Date:7/31/2014)... Reinberg HealthDay Reporter THURSDAY, ... rather than war experiences, are a source of drinking problems ... study suggests. Setbacks such as job loss, divorce and ... make as many as 13 percent of vets turn to ... has an important effect on mental health in the short ...
Breaking Medicine News(10 mins):Health News:ColumbiaDoctors of the Hudson Valley Welcomes Joseph M. Lee, M.D., M.S., R.P.V.I. 2Health News:ColumbiaDoctors of the Hudson Valley Welcomes Joseph M. Lee, M.D., M.S., R.P.V.I. 3Health News:The Independent Woman to Offer Financial Workshops in the Los Angeles Area - Developed by Women for Women 2Health News:NYU CDUHR researchers look at prescription opioid abuse among young adults in NYC 2Health News:NYU CDUHR researchers look at prescription opioid abuse among young adults in NYC 3Health News:NJ Top Dentists Approved, Clifton Dental Associates Now Actively Recommending the Application of Topical Fluoride Treatments to Adults 2Health News:Civilian Life, Not Combat, May Drive Many Veterans to Drink 2Health News:Civilian Life, Not Combat, May Drive Many Veterans to Drink 3
(Date:7/30/2014)... David L. Kaplan, Ph.D., will head the brand-new, web-only ... editor-in-chief. With the first issue slated for publication in ... in the rapidly burgeoning field of biomaterials, the study ... living or biological systems. , "This new journal is ... field of biomaterials over the past decade and the ...
(Date:7/30/2014)... of America (ESA) has elected ten new Fellows of ... acknowledges outstanding contributions to entomology in one or more ... following Fellows will be recognized during Entomology 2014 -- ... November 16-19, 2014 in Portland, Oregon. , DR. ... Department of Plant, Soil and Entomological Sciences at the ...
(Date:7/30/2014)... its new relationship with the International College of Neuropsychopharmacology ... to publish International Journal of Neuropsychopharmacology ( ... Frazer, Editor-in-Chief of IJNP said, "Our belief ... further facilitate the goal for the IJNP ... neuropsychopharmacology. The conversion of the IJNP to ...
Breaking Biology News(10 mins):ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2Entomological Society of America recognizes 2014 fellows 2Entomological Society of America recognizes 2014 fellows 3Entomological Society of America recognizes 2014 fellows 4Entomological Society of America recognizes 2014 fellows 5Entomological Society of America recognizes 2014 fellows 6Entomological Society of America recognizes 2014 fellows 7Entomological Society of America recognizes 2014 fellows 8Entomological Society of America recognizes 2014 fellows 9Entomological Society of America recognizes 2014 fellows 10Entomological Society of America recognizes 2014 fellows 11Entomological Society of America recognizes 2014 fellows 12Entomological Society of America recognizes 2014 fellows 13Entomological Society of America recognizes 2014 fellows 14Entomological Society of America recognizes 2014 fellows 15Entomological Society of America recognizes 2014 fellows 16Entomological Society of America recognizes 2014 fellows 17OUP to partner with the International College of Neuropsychopharmacology 2
Other Contents